News | October 11, 2024
OneSource unveils new brand identity at CPHI Milan
Aims to achieve CDMO sales of US$ 400 million by 2028
Aims to achieve CDMO sales of US$ 400 million by 2028
The company will now seek final approval from NCLT, Mumbai Bench, and upon its receipt, OneSource will proceed to seek listing approvals from the BSE and NSE
Revolutionary technology will further boost OneSource’s scientific services offerings
AMP-6 & AMP-8 are special purpose entities formed for purpose of setting up captive solar power projects in Karnataka
The product has been in-licensed from Strides and will be commercialized by Amneal
The product is bioequivalent and therapeutically equivalent to the RLD, Vascepa of Amarin
_256_384.jpg){kind=logo}
Veda Corporate Advisors was the exclusive financial advisor to SHPL and its shareholders.
Subscribe To Our Newsletter & Stay Updated
